Skip to main content
. 2022 Feb 9;14(4):860. doi: 10.3390/cancers14040860

Figure 1.

Figure 1

Regulation of BCR signaling and the therapeutic inhibition of BTK and PI3K in DLBCL and MCL. (Left panel) Antigen-dependent and chronic active BCR signaling; (Right panel) Tonic BCR signaling.